PL2512243T3 - Pozytywne modulatory allosteryczne receptora amidu chinoliny m1 - Google Patents

Pozytywne modulatory allosteryczne receptora amidu chinoliny m1

Info

Publication number
PL2512243T3
PL2512243T3 PL10841821.1T PL10841821T PL2512243T3 PL 2512243 T3 PL2512243 T3 PL 2512243T3 PL 10841821 T PL10841821 T PL 10841821T PL 2512243 T3 PL2512243 T3 PL 2512243T3
Authority
PL
Poland
Prior art keywords
positive allosteric
receptor positive
allosteric modulators
quinoline amide
quinoline
Prior art date
Application number
PL10841821.1T
Other languages
English (en)
Inventor
Scott D. Kuduk
Kelly-Ann Schlegel
Zhi-Qiang Yang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of PL2512243T3 publication Critical patent/PL2512243T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C07D215/60—N-oxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
PL10841821.1T 2009-12-17 2010-12-13 Pozytywne modulatory allosteryczne receptora amidu chinoliny m1 PL2512243T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28753509P 2009-12-17 2009-12-17

Publications (1)

Publication Number Publication Date
PL2512243T3 true PL2512243T3 (pl) 2016-09-30

Family

ID=44305688

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10841821.1T PL2512243T3 (pl) 2009-12-17 2010-12-13 Pozytywne modulatory allosteryczne receptora amidu chinoliny m1

Country Status (41)

Country Link
US (2) US9199939B2 (pl)
EP (1) EP2512243B1 (pl)
JP (1) JP5651708B2 (pl)
KR (1) KR101494059B1 (pl)
CN (1) CN102651970B (pl)
AR (1) AR079510A1 (pl)
AU (1) AU2010340142B2 (pl)
BR (1) BR112012014180A2 (pl)
CA (1) CA2782347C (pl)
CL (1) CL2012001605A1 (pl)
CO (1) CO6551729A2 (pl)
CR (1) CR20120327A (pl)
CY (1) CY1117726T1 (pl)
DK (1) DK2512243T3 (pl)
DO (1) DOP2012000167A (pl)
EA (1) EA022494B1 (pl)
EC (1) ECSP12011983A (pl)
ES (1) ES2575154T3 (pl)
GE (1) GEP201606506B (pl)
GT (1) GT201200201A (pl)
HN (1) HN2012001265A (pl)
HR (1) HRP20160574T1 (pl)
HU (1) HUE029734T2 (pl)
IL (1) IL220130A0 (pl)
MA (1) MA33920B1 (pl)
ME (1) ME02421B (pl)
MX (1) MX336774B (pl)
NI (1) NI201200107A (pl)
NZ (1) NZ600674A (pl)
PE (1) PE20121613A1 (pl)
PH (1) PH12012501222A1 (pl)
PL (1) PL2512243T3 (pl)
PT (1) PT2512243E (pl)
RS (1) RS54798B1 (pl)
SG (1) SG181719A1 (pl)
SI (1) SI2512243T1 (pl)
TN (1) TN2012000231A1 (pl)
TW (1) TWI412525B (pl)
UA (1) UA106406C2 (pl)
WO (1) WO2011084368A1 (pl)
ZA (1) ZA201204313B (pl)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
CN105037492A (zh) * 2010-02-11 2015-11-11 西北大学 二级结构稳定化的nmda受体调节剂及其用途
AR081402A1 (es) 2010-05-17 2012-08-29 Envivo Pharmaceuticals Inc Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin-3-il) benzo(b)tiofeno-2-carboxamida monohidrato
WO2011159554A1 (en) * 2010-06-15 2011-12-22 Merck Sharp & Dohme Corp. Tetrahydroquinoline amide m1 receptor positive allosteric modulators
WO2012158474A1 (en) * 2011-05-17 2012-11-22 Merck Sharp & Dohme Corp. N-linked quinolineamide m1 receptor positive allosteric modulators
JP6211509B2 (ja) 2012-03-02 2017-10-11 武田薬品工業株式会社 複素環化合物およびその用途
CA2872005A1 (en) 2012-05-08 2013-11-14 Forum Pharmaceuticals, Inc. Methods of maintaining, treating or improving cognitive function
WO2014077401A1 (ja) 2012-11-19 2014-05-22 武田薬品工業株式会社 含窒素複素環化合物
TW201512197A (zh) * 2013-08-30 2015-04-01 Hoffmann La Roche 吡咯并吡啶或吡唑并吡啶衍生物
MX2016001942A (es) * 2013-09-27 2016-06-02 Hoffmann La Roche Derivados de indol e indazol.
GB201317363D0 (en) 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
CA2930961A1 (en) * 2014-01-22 2015-07-30 F. Hoffmann-La Roche Ag Fluoro-naphthyl derivatives
WO2015190564A1 (ja) * 2014-06-13 2015-12-17 武田薬品工業株式会社 含窒素複素環化合物
WO2016009297A1 (en) 2014-07-18 2016-01-21 Pfizer Inc. Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators
EP3692991A1 (de) 2015-06-09 2020-08-12 Bayer Pharma Aktiengesellschaft Positiv allosterische modulatoren des muskarinergen m2 rezeptors
MA42769B1 (fr) * 2015-09-10 2019-12-31 Suven Life Sciences Ltd Dérivés de fluoroindole en tant que modulateurs allostériques positifs du récepteur muscarinique m1
WO2017099969A1 (en) * 2015-12-10 2017-06-15 Merck Sharp & Dohme Corp. Tetrahydroquinoxaline m1 receptor positive allosteric modulators
KR20180110132A (ko) 2016-02-16 2018-10-08 반더빌트유니버시티 무스카린성 아세틸콜린 수용체 m1의 양성 알로스테릭 조절제
WO2017151449A1 (en) * 2016-03-04 2017-09-08 Merck Sharp & Dohme Corp. M1 receptor positive allosteric modulator compounds and methods of use thereof
CN109689654A (zh) 2016-07-11 2019-04-26 拜耳医药股份有限公司 7-取代的1-吡啶基-萘啶-3-甲酰胺类及其用途
MX389592B (es) 2016-09-02 2025-03-20 Suven Life Sciences Ltd Moduladores alostericos positivos del receptor m1 muscarinico
JOP20190045A1 (ar) 2016-09-14 2019-03-14 Bayer Ag مركبات أميد حمض 1- أريل-نفثيريدين-3-كربوكسيليك مستبدلة في الموضع 7 واستخدامها.
WO2018063552A1 (en) 2016-09-30 2018-04-05 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m1
EA035599B1 (ru) * 2017-04-13 2020-07-14 Сувен Лайф Сайенсиз Лимитед Позитивные аллостерические модуляторы мускариновых m1-рецепторов
CA3068209A1 (en) * 2017-06-20 2018-12-27 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2018235838A1 (ja) 2017-06-20 2018-12-27 武田薬品工業株式会社 複素環化合物
MA50464A (fr) * 2017-10-27 2021-06-02 Suven Life Sciences Ltd Amides polycycliques utilisés en tant que modulateurs allostériques positifs du récepteur muscarinique m1
EP3858828A4 (en) * 2018-09-28 2022-07-06 Takeda Pharmaceutical Company Limited HETEROCYCLIC COMPOUND
EP3858823A4 (en) 2018-09-28 2022-07-06 Takeda Pharmaceutical Company Limited Condensed-cyclic compound
EP3867254B1 (en) 2018-10-17 2023-05-31 Suven Life Sciences Limited Pyrrolo-pyridazine derivatives as muscarinic m1 receptor positive allosteric modulators
WO2020086864A1 (en) 2018-10-24 2020-04-30 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m1
WO2023114224A1 (en) 2021-12-13 2023-06-22 Sage Therapeutics, Inc. Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL135495A (en) * 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
KR20030027094A (ko) 2000-08-29 2003-04-03 야마노우치세이야쿠 가부시키가이샤 신규 에스테르 또는 아미드 유도체
EP1596867A4 (en) 2003-02-19 2006-03-22 Merck & Co Inc TREATMENT OF PSYCHOSIS WITH A MUSCARIN M1 RECEPTOR ECTOPIC ACTIVATOR
MXPA05009722A (es) * 2003-03-10 2006-03-09 Schering Corp Inhibidores heterociclicos de cinasa: metodos de uso y sintesis.
SE0302139D0 (sv) * 2003-07-28 2003-07-28 Astrazeneca Ab Novel compounds
JP4740152B2 (ja) * 2003-12-23 2011-08-03 セロドス アクスイェ セルスカブ 末梢性５−ｈｔ受容体の修飾因子
US20070185090A1 (en) * 2004-03-17 2007-08-09 Jakob Busch-Petersen Muscarinic acetylchoine receptor antagonists
JP5192389B2 (ja) * 2005-12-05 2013-05-08 メルク・シャープ・エンド・ドーム・コーポレイション キノロンｍ１レセプター陽性アロステリックモジュレータ
CN101321733A (zh) * 2005-12-05 2008-12-10 默克公司 喹诺酮m1受体阳性变构调节剂
US8106073B2 (en) 2007-11-30 2012-01-31 Astrazeneca Ab Quinoline derivatives 057
EP2268280B1 (en) * 2008-03-21 2013-04-24 Merck Sharp & Dohme Corp. Quinolizidinone M1 receptor positive allosteric modulators
NZ592961A (en) 2008-11-20 2012-09-28 Merck Sharp & Dohme Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
CA2750708A1 (en) 2009-02-23 2010-08-26 Merck Sharp & Dohme Corp. Pyrazolo [4,3-c] cinnolin-3-one m1 receptor positive allosteric modulators
EP2421366B1 (en) 2009-04-20 2013-08-28 Merck Sharp & Dohme Corp. Heterocyclic fused cinnoline m1 receptor positive allosteric modulators
AU2010286683B9 (en) 2009-08-31 2014-09-04 Merck Sharp & Dohme Llc Pyranyl aryl methyl benzoquinazolinone M1 receptor positive allosteric modulators
EP2490692B1 (en) 2009-10-21 2016-11-16 Merck Sharp & Dohme Corp. Quinolinone-pyrazolone m1 receptor positive allosteric modulators
EP2501231B1 (en) 2009-11-20 2016-12-21 Merck Sharp & Dohme Corp. Quinolizidinone carboxamide m1 receptor positive allosteric modulators
US8664387B2 (en) 2009-12-14 2014-03-04 Merck Sharp & Dohme Corp. Pyridoquinazolinone M1 receptor positive allosteric modulators
US8383638B2 (en) 2009-12-21 2013-02-26 Merck Sharp & Dohme Aminobenzoquinazolinone M1 receptor positive allosteric modulators
EP2575454B1 (en) 2010-05-28 2018-08-29 Merck Sharp & Dohme Corp. Naphthalene carboxamide m1 receptor positive allosteric modulators
US8557992B2 (en) 2010-06-15 2013-10-15 Merck Sharp & Dohme Corp. Heterocyclic fused phenanthrolinone M1 receptor positive allosteric modulators
WO2011159554A1 (en) 2010-06-15 2011-12-22 Merck Sharp & Dohme Corp. Tetrahydroquinoline amide m1 receptor positive allosteric modulators
WO2012158474A1 (en) 2011-05-17 2012-11-22 Merck Sharp & Dohme Corp. N-linked quinolineamide m1 receptor positive allosteric modulators

Also Published As

Publication number Publication date
NZ600674A (en) 2013-05-31
KR101494059B1 (ko) 2015-02-16
PE20121613A1 (es) 2012-12-02
US20160075656A1 (en) 2016-03-17
EA022494B1 (ru) 2016-01-29
CN102651970A (zh) 2012-08-29
US9199939B2 (en) 2015-12-01
GT201200201A (es) 2015-05-20
CA2782347C (en) 2014-09-23
BR112012014180A2 (pt) 2015-09-15
ES2575154T3 (es) 2016-06-24
CO6551729A2 (es) 2012-10-31
TWI412525B (zh) 2013-10-21
GEP201606506B (en) 2016-07-11
JP5651708B2 (ja) 2015-01-14
EP2512243A1 (en) 2012-10-24
CN102651970B (zh) 2014-11-12
CA2782347A1 (en) 2011-07-14
EP2512243A4 (en) 2013-05-29
NI201200107A (es) 2012-10-30
MX2012007013A (es) 2012-07-03
ME02421B (me) 2016-09-20
EA201290519A1 (ru) 2013-01-30
MA33920B1 (fr) 2013-01-02
WO2011084368A1 (en) 2011-07-14
CR20120327A (es) 2012-07-30
DK2512243T3 (en) 2016-07-25
KR20120084324A (ko) 2012-07-27
SI2512243T1 (sl) 2016-07-29
CL2012001605A1 (es) 2012-10-05
CY1117726T1 (el) 2017-05-17
SG181719A1 (en) 2012-07-30
DOP2012000167A (es) 2012-12-31
JP2013514358A (ja) 2013-04-25
AU2010340142A1 (en) 2012-06-14
TW201130824A (en) 2011-09-16
HUE029734T2 (en) 2017-03-28
US20120252808A1 (en) 2012-10-04
ECSP12011983A (es) 2012-07-31
RS54798B1 (sr) 2016-10-31
AR079510A1 (es) 2012-02-01
AU2010340142B2 (en) 2014-05-08
EP2512243B1 (en) 2016-04-06
ZA201204313B (en) 2016-01-27
MX336774B (es) 2016-01-28
PH12012501222A1 (en) 2012-11-05
UA106406C2 (ru) 2014-08-26
HRP20160574T1 (hr) 2016-06-17
IL220130A0 (en) 2012-07-31
TN2012000231A1 (en) 2013-12-12
HN2012001265A (es) 2015-09-07
PT2512243E (pt) 2016-06-08
HK1170122A1 (zh) 2013-02-22

Similar Documents

Publication Publication Date Title
ZA201204313B (en) Quinoline amide m1 receptor positive allosteric modulators
IL212573A0 (en) Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
GB2467192B (en) Connection device
EP2501231A4 (en) POSITIVE ALLOSTERIC CHINOLIZIDINONE CARBOXAMIDE M1 RECEPTOR MODULATORS
GB201009952D0 (en) Hinge development
ZA201201205B (en) Pyranyl aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
GB201004739D0 (en) Receptor modulators
PL2513397T3 (pl) Zawias
TWM386742U (en) Hinge
EP2449197A4 (en) HINGE DEVICE
GB2479551B (en) Hinged connection device
ZA201204527B (en) Crth2 modulators
TWM387473U (en) Hinge
GB201013594D0 (en) Hinge arrangements
GB201015846D0 (en) Hinge
TWM385907U (en) Hinge
TWM373956U (en) Quick connection structure for hinge
GB0909723D0 (en) Hinge
GB0913110D0 (en) Electro-optic device
TWM385903U (en) dual-axial hinge device
TWM385905U (en) Hinge
TWM386741U (en) Hinge
GB201200639D0 (en) Hinge
GB0902525D0 (en) Pharmacophores
TWM401183U (en) Gateway reminder device